GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2025
0mins
Source: Globenewswire
Interim Study Results: The Independent Data Monitoring Committee has recommended continuing the Phase 2a study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) after interim results showed it to be safe and well-tolerated in the first 12 patients evaluated, with no significant safety concerns.
Future Expectations: GRI Bio anticipates reporting interim biomarker data in Q2 2025 and topline results in Q3 2025, highlighting the potential of GRI-0621 as a much-needed treatment option for IPF, which currently has limited and side-effect-prone therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
